IL28B Proteins, Antibodies, cDNA Clones Research Reagents

IFNL3 (Interferon Lambda 3, also known as IL28B; IL28C; IL-28B; IL-28C; IFN-lambda-3; IFN-lambda-4), located on 19q13.2, is a Protein Coding gene. The gene produces a 21706 Da protein composed of 196 amino acids. IL28B is a class II cytokine receptor (e.g., IFNAR1) ligand related to type I interferons. It has a conserved cysteine pattern and amphipathic profile similar to other helical cytokine family members. IL28B functions in Up-regulating MHC class I antigen expression. Diseases such as Hepatitis C Virus and Htlv-1 Associated Myelopathy/Tropical Spastic Paraparesis are associated with IFNL3.

IL28B Protein (3)

    IL28B Antibody (6)

      IL28B cDNA Clone (16)

      NM_172139.2

      In expression vector

      BC130314

      In expression vector

      In lentiviral vector

      NM_177396.1

      克隆载体 cDNA 产品

      In lentiviral vector

      IL28B Lysate (2)

        IL28B 分子背景

        Interleukin-28B (IL-28B) also known as Interferon lambda-3 and IFN-lambda-3, belongs to the type III interferon family of cytokines and are highly similar to IL-29. IL-28B belongs to the newly described interferon lambda (IFNλ) family of cytokines. IL-28B is a cytokine with immunomodulatory activity. It functions in Up-regulating MHC class I antigen expression. IL-28B displays potent antiviral activity and antitumor activity. This cytokine serves as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IL28RA. The ligand/receptor complex seems to signal through the Jak-STAT pathway. IL-28B, like IL-12, is capable of robustly enhancing adaptive immunity. Moreover, we describe for the first time how IL-28B reduces regulatory T-cell populations during DNA vaccination, whereas IL-12 increases this cellular subset. We also show that IL-28B, unlike IL-12, can increase the percentage of splenic CD8+ T cells in vaccinated animals and that these cells are more granular and have higher antigen-specific cytolytic degranulation compared with cells taken from animals that received IL-12 as an adjuvant.

        IL28B 参考文献

        • Ge D, et al.. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 461(7262): 399-401.
        • Morrow MP, et al.. (2009) Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood. 113(23): 5868-77.
        • Sheppard P, et al.. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 4(1): 63-8.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.